Targeting macrophage liver X receptors by hydrogel-encapsulated T0901317 reduces atherosclerosis without effect on hepatic lipogenesis.

Chuanrui MaKe FengXiaoxiao YangZhimou YangZhongyan WangYuna ShangGuanwei FanLipei LiuShu YangXiaoju LiJihong HanYajun DuanYuanli Chen

Published in: British journal of pharmacology (2021)

Our study demonstrates that D-Nap-GFFY-T0901317 reduces atherosclerosis without effect on hepatic lipogenesis by targeting macrophage LXRs selectively, indicating its potential application for atherosclerosis treatment.

Keyphrases

cardiovascular disease
adipose tissue
type diabetes
metabolic syndrome
skeletal muscle
combination therapy
wound healing